Channel destocking, higher RM costs impact margins
Aurobindo Pharma (ARBP)'s 2QFY22 results came in below our estimates, weighed by decline in ARV/API sales and an increase in raw material (RM)...
229 Views
Aurobindo Pharma Limited: Significant Revenue Miss Due to US, ARVs
About the stock: Aurobindo is a significant global generics player with 28 manufacturing facilities, including eight key formulations facilities in...
199 Views
AUROPHARMA: Expect Revenue and PAT CAGR of 9.6% and 13.9%
We expect revenue and PAT CAGR of 9.6% and 13.9% over the period FY20-FY23E and recommend 'BUY' with TP of Rs 1,100/share.
265 Views
Aurobindo Pharma (4QFY21): Soft quarter, outlook remains strong. Maintain BUY
We tweak our estimates and revise TP to INR1,075/sh, based on 16x FY23e EPS and NPV of INR50 for the PLI opportunity. Maintain BUY Q4 revenue...
255 Views